DiaCarta Gains CE Mark for COVID-19 Test that Identifies New Variants

Molecular diagnostics company DiaCarta’s new QuantiVirus SARS-CoV-2 variant detection test has received a CE mark.

DiaCarta says the multiplex test, which runs on commonly available quantitative polymerase chain-reaction (qPCR) cyclers, is based on the company’s proprietary synthetic nucleic acid analogs.

The test screens for the SARS-CoV-2 coronavirus that causes COVID-19 and it can differentiate between major new variants, including the Alpha, Beta, Gamma, Delta, Delta Plus, Epsilon and Kappa variants.